Hims & Hers Health Faces a Two-Front War as Novo Nordisk Goes Direct to Consumers
NEW YORK, April 14 —
Novo Nordisk launched a first-ever direct-to-consumer Wegovy subscription plan. The company with the most to lose: Hims & Hers Health.
- HIMS trades at $21.29, or 15.0x forward earnings, on $2.3bn in trailing twelve-month revenue
- Novo's subscription cuts out the middleman on branded Wegovy, pressuring HIMS compounded GLP-1 margins
- Watch for: Novo's subscription pricing details vs. HIMS compounded GLP-1 prices, plus any customer churn data tied to a newly disclosed cybersecurity breach
What Actually Happened
Two things hit at once. Novo Nordisk launched a subscription plan selling Wegovy directly to consumers — designed to lower patient costs and pull volume away from compounded alternatives. Hims & Hers built its GLP-1 business by offering compounded semaglutide at lower prices than the branded drug. If Novo closes the price gap, HIMS loses its main selling point.
Separately, HIMS disclosed that its customer support system was hacked. For a telehealth company whose model runs on trust with sensitive health data, the timing is brutal.
The picture is not all bad. HIMS recently struck a partnership with Novo Nordisk on GLP-1 distribution, giving it a seat at the table even as Novo builds its own direct channel. And the FDA reversed course on peptide regulation in a way that helps telehealth GLP-1 providers, keeping the compounding window open longer than bears expected.
The Catch
The bull case for HIMS has always been simple: cheapest, easiest way to get GLP-1 drugs. Novo going direct rewrites that calculation. The partnership between the two companies sounds reassuring. But partnerships with your largest competitor tend to favor the party that controls supply. Novo has the molecule. HIMS has the app.
The cybersecurity breach is harder to size. Telehealth customers share prescription history, payment data, and personal health information. Even a limited breach damages the trust that makes someone comfortable ordering weight loss medication through their phone. No churn data is available yet, but the next quarter's subscriber numbers will tell the story.
Bottom Line
At 15.0x forward earnings on $2.3bn in revenue, HIMS is not priced for perfection. But the stock was priced for steady GLP-1 growth, and Novo just complicated that bet. The FDA's peptide leniency and the existing Novo partnership keep HIMS in the game. Neither eliminates the core risk: the brand-name drug maker is now competing for the same price-sensitive customers HIMS built its growth on. The number to watch is the spread between Novo's subscription price and what HIMS charges for compounded semaglutide. If that gap narrows below $100/month, the compounding thesis falls apart.
For a full financial breakdown of Hims & Hers Health, generate a free HIMS report on Basis Report.
Basis Report does not hold positions in securities discussed. This is not investment advice.